HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices
18 Abril 2007 - 3:41PM
PR Newswire (US)
NEW YORK, April 18 /PRNewswire/ -- HealthShares(TM) Inc., an
investment company with a series of 20 underlying fund portfolios,
today announced it has been informed by Standard & Poor's, the
calculating agent for the HealthShares(TM) Indices, that effective
at the opening of trading on Monday April 23, 2007, Neurochem Inc.
(NASDAQ:NRMX) will replace New River Pharmaceuticals (NASDAQ:NRPH)
in the HealthShares(TM) Neuroscience Index. Additionally, Aspreva
Pharmaceuticals Corp. (NASDAQ:ASPV) will replace New River
Pharmaceuticals in the HealthShares(TM) Composite Index. Companies
included in the Neuroscience Index are engaged in the research,
clinical development and commercialization of therapeutic agents
for the treatment of a wide variety of neurological and psychiatric
disorders including Alzheimer's, Parkinson's, Huntington's,
schizophrenia, anxiety, depression, epilepsy, pain and sleep
disorders. About HealthShares(TM) XShares Advisors LLC, a financial
services company based in New York, is the creator of the
HealthShares(TM) family of Exchange Traded Funds (ETFs).
HealthShares(TM) ETFs are organized into therapeutic 'Verticals'
and represent specific areas of the healthcare, life science and
biotechnology industries. Each Vertical addresses a distinct
sub-segment of healthcare, such as the diagnosis and treatment of
specific therapeutic areas (e.g. cardiology, cancer, infectious
disease, etc.) and the development of medical devices (e.g.
orthopedic repair, cardio devices, etc.). Each ETF tracks an index
of 22-25 stocks and offers institutional and individual investors a
more precise financial instrument that leverages the potential of
healthcare investing while mitigating the risks of single stock
picking. For more information, visit the company's website at:
http://www.healthsharesinc.com/. About XShares XShares Advisors
LLC, a subsidiary of XShares Group LLC, is a registered investment
advisor that provides investment advisory services to Exchange
Traded Funds. XShares also partners with major institutions and
index providers seeking to bring innovative Exchange Traded Funds
to market using its administrative platform. In addition, XShares
creates and licenses distinctive intellectual property for its
ETFs, developing products that allow for innovative trading
strategies and alternative investments for the financial community.
For more information, visit the company's website at
http://www.xsharesadvisors.com/. An Investor should consider the
fund's investment objective, risks, charges and expenses carefully
before investing. For this and more complete information about the
fund call 800.925.2870 or visit the website
http://www.healthsharesinc.com/ for a prospectus. Please read the
prospectus carefully before investing. There are risks involved
with investing in ETFs including possible loss of money.
HealthShares(TM) are not actively managed and are subject to risks
similar to stocks, including those related to short selling and
margin maintenance. HealthShares(TM) ETFs are subject to increased
risks associated with investing in a specific sector compared to a
more diversified investment, as well as unique risks associated
with the healthcare and biotechnology sector (i.e., government
regulation, patent regulation, etc.). The prospectus is not an
offer to buy or sell the portfolio shares, nor is the fund
soliciting an offer to buy its shares in any jurisdiction where the
offer or sale is not permitted. HealthShares(TM) Exchange Traded
Funds are distributed by ALPS Distributors, Inc. HSI 208 exp.
5/31/07 DATASOURCE: XShares Advisors LLC CONTACT: Melissa Kanter of
Edelman, +1-212-704-8261, or , for XShares Web site:
http://www.xsharesadvisors.com/ http://www.healthsharesinc.com/
Copyright
New River (NASDAQ:NRPH)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
New River (NASDAQ:NRPH)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about New River Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de New River Pharmaceuticals Inc. (MM) Artículos de Noticias